Retinoblastoma
Conditions
Interventions
Tumour tissues of 6 eyes from 6 patients who underwent enucleation from 2019 to 2021 at Hong Kong Eye Hospital (Retinoblastoma organoid (RBO) culture, genetic analyses and chemosensitivity profiling):
6-8 new RB patients who are undergoing enucleation from 2022 to 2025 (Medical record review, retinoblastoma organoid (RBO)/non-tumor retinal organoid (RO) culture, genetic analyses and chemosensitivit
Sponsors
Research Office, Health Bureau
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Diagnosed with RB - Undergo enucleation in Hong Kong from 2019 to 2025 with frozen RB primary cells/tissues accessible by our project team - Agree and/or have parent(s) and/or guardian(s) who agree to join the study by signing written assent and/or informed consent or had parent(s) and/or guardian(s) who signed a former written informed consent which stated their acknowledgement of the use of the collected tissues for future studies
Exclusion criteria
Exclusion criteria: Diagnosed with infectious disease(s) at the time of operation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A panel of RBOs derived from Hong Kong RB patient tumours collected from 2019 to 2025;Histopathological, cellular phenotype, genetics, and chemosensitivity profiles of the RBOs;Histopathological, cellular phenotype, and genetics profiles of the original RB tumours collected from 2022 to 2025; | — |
Secondary
| Measure | Time frame |
|---|---|
| Relations between the RBOs and their original tumours in terms of histopathological, cellular phenotype, and genetics profiles;Relations between chemosensitivity and genetic profiles of the RBOs;A standard operating protocol/pipeline for RBO culturing, characterisation, and maintenance; | — |
Countries
Hong Kong
Contacts
Public ContactDr Yam Cheuk Sing Jason
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong
Outcome results
None listed